Biomarker Discovery & Development, Almac, Biomarkers, discovery, development, FFPE, formalin fixed paraffin embedded, biomarker solutions, companion diagnostic development, bioinformatics, proprietary technology, R & D

Biomarker Discovery & Development

Almac MCDx

Almac partners with the biopharmaceutical industry to provide biomarker discovery and development solutions ranging from pre-clinical biomarker discovery, through to full companion diagnostic development, biomarker clinical trial management and clinical test delivery from our CLIA lab, we apply these tests as early as phase I for trial enrichment.

We have an expert team with a wide range of experience. We have a portfolio of proprietary discovery arrays and extensive experience and expertise working with formalin fixed paraffin embedded (FFPE) tissue. We utilise this expertise, experience and innovative technology developing diagnostics for our partners and in the development of our own pipeline of molecular diagnostics.

We went looking for new biomarkers and we discovered the future, click here to visit our new microsite and learn about the potential of multiplex companion diagnostics. 



Almac Advantage

Internal Biomarker Discovery

Our internal biomarker discovery team are focused on the discovery of prognostic and predictive tests as well as tests for improved diagnosis of cancer and developing technical solutions to support this work.

Proprietary Technology

We have our own portfolio of proprietary discovery arrays Xcel™ for studies involving multiple and cross disease areas and Cancer DSA® for specific disease indications.


We have extensive experience and expertise working with formalin fixed paraffin embedded (FFPE) tissue. FFPE is the primary method of storing tissues within oncology and we utilise our proprietary technology to deliver outstanding results on FFPE data.

Discovery to Delivery

At Almac we have the capacity to work with you from early biomarker discovery right through to delivery of tests. Our CLIA registered lab enables us to use novel tests to stratify and enrich prospective clinical trails.

Flash replacement image